Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice (Q38322940)

2 September 2017

Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice (English)

1 reference

2 September 2017

Yun-Wei Shi

1

1 reference

2 September 2017

Cai-Ping Wang

2

1 reference

2 September 2017

Lei Liu

3

1 reference

2 September 2017

Yang-Liu Liu

4

1 reference

2 September 2017

Xing Wang

5

1 reference

2 September 2017

Ye Hong

6

1 reference

2 September 2017

Zhen Li

7

1 reference

2 September 2017

Ling-Dong Kong

8

1 reference

2 September 2017

3 August 2012

1 reference

Molecular Nutrition and Food Research

2 September 2017

1 reference

2 September 2017

56

1 reference

2 September 2017

9

1 reference

2 September 2017

1433-1444

1 reference

Relationship of uric acid with progression of kidney disease.

2 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Serum uric acid levels and the risk of type 2 diabetes: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Molecular physiology of urate transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Renal effects of Tamm-Horsfall protein (uromodulin) deficiency in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Current management of gout in patients unresponsive or allergic to allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Resveratrol in human cancer chemoprevention--choosing the 'right' dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Pharmacometrics of stilbenes: seguing towards the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Resveratrol and health--a comprehensive review of human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Transport, stability, and biological activity of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

A pilot study of evaluation of the antioxidative activity of resveratrol and its analogue in a 6-month feeding test in young adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Challenges of translating basic research into therapeutics: resveratrol as an example

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

What is new for an old molecule? Systematic review and recommendations on the use of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Dose translation from animal to human studies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Safety studies conducted on high-purity trans-resveratrol in experimental animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Metabolism and bioavailability of trans-resveratrol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Resveratrol bioavailability and toxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Three major metabolites of mulberroside A in rat intestinal contents and feces

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Grape Extract, Resveratrol, and Its Analogs: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Resveratrol, pterostilbene, and piceatannol in vaccinium berries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Biotransformation of mulberroside A from Morus alba results in enhancement of tyrosinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201100828

21 January 2018

Identifiers

DOI

10.1002/MNFR.201100828

1 reference

2 September 2017

1 reference